Faspik, 400 mg sachet 12 pcs

Name: Faspik, 400 mg sachet 12 pcs
SKU: 223337
Availability: InStock

€3.64

EAN: 4603619000261 SKU: 223337 Categories: Medicine, Pain and inflammation

Description

Joint pain (arthralgia), Migraine, Colds, Arthrosis and arthritis, Painful menstruation (algodysmenorrhea), Pain after injuries and operations, Flu, Pain, Neuralgia, Increased body temperature, Rheumatoid arthritis, Periarthritis, Neck pain, Myalgia (muscle pain), Back pain, Headache, Toothache, Osteoarthritis, Sore throat.Li>Fever syndrome of various genesis.

Pain syndrome of different etiology (including sore throat, headache, migraine, toothache, neuralgia, post-operative pain, post-traumatic pain, primary algodysmenorrhea).

Inflammatory and degenerative diseases of the joints and spine (including rheumatoid arthritis, ankylosing spondylitis).

Active ingredient

Ibuprofen

Composition

Active ingredient

buprofen 400 mg;

Associates:

L-arginine,

sodium bicarbonate,

Sodium saccharinate,

aspartame,

apricot flavoring,

saccharose.

How to take, the dosage

The drug is taken orally, during or after meals. The pellets should be dissolved in 50-100 ml of water before intake.
Dosages for adults according to indications:

ankylosing spondylitis: 400-600 mg 3-4 times daily;

rheumatoid arthritis: 800 mg 3 times daily;

pain syndrome: In a daily dose of up to 1200 mg in several doses;

posttraumatic pain: in a daily dose of 1600-2400 mg in several doses;

algodysmenorrhea: 400 mg 3-4 times a day.

Dosage for adolescents from 12 years of age as indicated:

juvenile rheumatoid arthritis: at a daily dose of 30-40 mg/kg in 3-4 doses in equal parts;

high body temperature: from 39.2 ° C – in a daily dose of 10 mg/kg, below 39.2 ° C – 5 mg/kg;

pain syndrome: in a daily dose of 5-10 mg/kg.

Maximum daily doses of Faspik: for children – 40 mg/kg, for adults – 1200 mg.
In rheumatoid arthritis administration of higher doses is recommended, but not more than 2400 mg per day. To overcome morning stiffness in arthritis, the first dose should be taken immediately after waking up.
The duration of Faspik administration: as an antipyretic – up to 3 days, as an analgesic – up to 5 days. The drug dose is reduced in patients with liver, kidney or heart dysfunction.

Interaction

acetylsalicylic acid (ASA): its antiaggregant effect is reduced (which may increase the incidence of acute coronary failure in patients receiving ASA as an antiaggregant);

other NSAIDs (including ASA): increased likelihood of gastrointestinal side effects;

methotrexate: increases its plasma concentration;

furosemide, thiazide diuretics: may decrease their effectiveness due to sodium retention due to inhibition of prostaglandin synthesis in the kidneys;

indirect anticoagulants, antiaggregants, fibrinolytics: increases their action, increasing the risk of hemorrhagic complications;

vasodilators (including angiotensin-converting enzyme inhibitors and slow calcium channel blockers): decreases their hypotensive effects;

tacrolimus: increases the likelihood of nephrotoxic effects;

caffeine: increases the analgesic effects of ibuprofen;

zidovudine: increased risk of hematoma and hemarthrosis in HIV-infected patients with concomitant hemophilia;

myelotoxic agents: increases the manifestation of hematotoxicity of ibuprofen;

hepatic microsomal enzyme inhibitors: decreases the risk of hepatotoxic effects;

hepatic microsomal enzyme inducers (tricyclic antidepressants, barbiturates, phenylbutazone, phenytoin, rifampicin, ethanol): increased risk of severe hepatotoxic reactions due to increased active and hydroxylated metabolites);

anticoagulants, thrombolytic agents (streptokinase, urokinase, alteplase): increased likelihood of bleeding;

plicamycin, cefotetan, cefoperazone, cefamandole, valproic acid: increased incidence of hypoprothrombinemia;

gold preparations, cyclosporine: nephrotoxicity of ibuprofen increases due to its increased effect on prostaglandin synthesis in the kidneys;

cyclosporin: Its plasma concentration increases and, consequently, the risk of hepatotoxic effects;

antacids, colestyramine: absorption of ibuprofen decreases;

ethanol, estrogens, glucocorticosteroids, colchicine: may develop ulcerogenic effects with bleeding;

insulin, oral hypoglycemic drugs: their effects are increased, which may require dosage adjustment;

drugs that block tubular secretion: ibuprofen excretion is reduced and plasma concentrations are increased;

phenytoin, lithium, digoxin: the possibility of increasing their plasma concentrations is not excluded.

Special Instructions

In patients with infection the drug should be administered with caution and on condition of adequate antimicrobial therapy, since ibuprofen may mask objective and subjective signs of infection.

Patients with allergic reactions and bronchial asthma (including a history) have an increased risk of bronchospasm on ibuprofen therapy.

In prolonged use of NSAIDs, there is a possibility of developing analgesic nephropathy.

In case of gastrointestinal bleeding symptoms, discontinue Faspik.

Patients who notice visual disturbances during therapy should stop taking the drug and consult an ophthalmologist.

The risk of side effects is reduced when taking Faspic in the lowest effective dose for the shortest possible course.

At the time of treatment, the peripheral blood count and the functional status of the kidneys and liver should be monitored periodically. In 48 hours, Faspik should be discontinued in patients who are indicated for 17-ketosteroids testing.

In case of signs of gastropathy, close monitoring of patient’s condition is required, including fecal occult blood test, blood test to determine hematocrit and hemoglobin, as well as esophagogastroduodenoscopy. To prevent gastropathy associated with taking NSAIDs, it is recommended to combine the drug with prostaglandin E agents (e.g., misoprostol).

Ibuprofen may have a negative effect on female fertility, so it is not recommended for women during pregnancy planning.

At the time of treatment, you should refrain from drinking alcoholic beverages.

One tablet of Faspik contains 16.7 mg of sucrose. The sucrose content of 400 mg granules is 0.18 IU in 1 packet and 0.54 IU in the maximum daily dose.

Influence on ability to drive motor transport and operating complex mechanisms: Patients are recommended to refrain from performing any work requiring fast reactions and increased attention, including driving a car and operating complex mechanisms during the therapy.

The use of Faspik in pregnant and lactating women is contraindicated.

Application in children Faspic in doses of 200 and 400 mg is contraindicated in children under 12 years of age, in doses of 600 mg in children and adolescents under 18 years of age.

In renal dysfunction. Progressive renal disease and severe renal failure with creatinine clearance (CK) less than 30 ml/min are contraindications for administration of Faspik. In chronic renal failure (CKR 30-60 ml/min) the drug should be used with caution.

In liver function disorders. Severe hepatic insufficiency and active liver disease are considered contraindications to administration of Faspik. In liver failure the drug should be used with caution.

Contraindications

Hypersensitivity to any of the ingredients in the drug.

Hypersensitivity to acetylsalicylic acid or other NSAIDs in the history.

Erotic ulcerative diseases of the gastrointestinal tract (including acute gastric and duodenal ulcer, Crohn’s disease, ulcerative colitis).

“Aspirin” asthma.

Hemophilia and other clotting disorders (including hypocoagulation), hemorrhagic diathesis.

Bleeding of any etiology.

Pregnancy.

Lactation period.

Childhood under 12 years.

Visual nerve disease.

Caution is required in the following cases:

older age;

heart failure;

arterial hypertension;

hepatic cirrhosis with portal hypertension;

hepatic and/or renal insufficiency, nephrotic syndrome, hyperbilirubinemia;

gastric and duodenal ulcer (in anamnesis), gastritis, enteritis, colitis;

blood disorders of unclear etiology (leukopenia and anemia).

Side effects

dyspnea, bronchospasm;

gastrointestinal tract (GIT): mouth pain, oral mucosa irritation or dryness, aphthous stomatitis, gum mucosa ulceration, pancreatitis, NSAID gastropathy (diarrhea, constipation, decreased appetite, heartburn, flatulence, nausea, vomiting, abdominal pain, GI mucosa ulceration, in some cases complicated by perforation and bleeding);

central and peripheral nervous system: hallucinations, nervousness, insomnia, confusion, irritability, dizziness, drowsiness, anxiety, psychomotor agitation, depression, headache, aseptic meningitis (more often in patients with autoimmune diseases);

cardiovascular system: increased blood pressure, tachycardia, heart failure;

blood organs: agranulocytosis, thrombocytopenic purpura, thrombocytopenia, leukopenia, anemia (including hemolytic and aplastic);

renal system: Nephrotic syndrome (edema), cystitis, polyuria, allergic nephritis, acute renal failure;

hepatobiliary system: hepatitis; visual organ: Conjunctival and eyelid edema (allergic genesis), blurred vision or double vision, toxic optic nerve damage, eye irritation and dryness, scotoma;

hearing organ: ringing, tinnitus, reduced hearing;

allergic reactions: Itching, skin rash (usually urtic and erythematous), allergic rhinitis, eosinophilia, fever, bronchospasm or shortness of breath, anaphylactoid reactions, Quincke’s edema, anaphylactic shock, toxic epidermal necrolysis (Lyell syndrome), erythema multiforme exudative (including Stevens-Johnson syndrome);

laboratory findings: increased bleeding time, serum creatinine concentration and hepatic transaminase activity, decreased creatinine clearance, blood glucose concentration, hemoglobin, or hematocrit.

Long use of Faspik in high doses increases the risk of gastrointestinal mucosal ulceration, bleeding (gingival, gastrointestinal, hemorrhoidal or uterine) and visual impairment (optic nerve damage, color vision disorders and scotoma development).

Overdose

In overdose of ibuprofen the following symptoms may occur: drowsiness, lethargy, nausea, vomiting, abdominal pain, acute renal failure, metabolic acidosis, tinnitus, headache, depression, decreased blood pressure, tachycardia, bradycardia, atrial fibrillation, coma, respiratory arrest.

Pregnancy use

The use of Faspik is contraindicated for pregnant and lactating women.

Similarities

Nurofen, Nurofen Express, Brufen, Ibuprofen, Dolgit, Ibuprofen-Chemopharm, Nurofen Forte, MIG 400, Faspik, Nurofen Express Lady, Nurofen Express Forte, Nurofen Children, Next Uno Express, Nurofast

Additional information

Weight	0.057 kg
Shelf life	3 years. Do not use after the expiration date printed on the package.
Conditions of storage	Keep out of reach of children at temperatures up to 25 ° C.
Manufacturer	Zambon S.p.A., Italy
Medication form	granules for preparation of oral solution
Brand	Zambon S.p.A.